Your browser doesn't support javascript.
loading
Erratum to: A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
Reisner, Colin; Fabbri, Leonardo M; Kerwin, Edward M; Fogarty, Charles; Spangenthal, Selwyn; Rabe, Klaus F; Ferguson, Gary T; Martinez, Fernando J; Donohue, James F; Darken, Patrick; St Rose, Earl; Orevillo, Chad; Strom, Shannon; Fischer, Tracy; Golden, Michael; Dwivedi, Sarvajna.
Afiliação
  • Reisner C; Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA. creisner@pearltherapeutics.com.
  • Fabbri LM; Department of Medicine, University of Modena and Reggio Emilia, NOCSAE, Modena, Italy.
  • Kerwin EM; Clinical Research Institute of Southern Oregon, Medford, OR, USA.
  • Fogarty C; Spartanburg Medical Research, Spartanburg, NC, USA.
  • Spangenthal S; American Health Research, Charlotte, NC, USA.
  • Rabe KF; Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany.
  • Ferguson GT; Department of Medicine, Christian-Albrechts University Kiel, Kiel, MI, USA.
  • Martinez FJ; Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA.
  • Donohue JF; Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College; New York-Presbyterian Hospital/Weill Cornell MedicalCenter, New York, NY, USA.
  • Darken P; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • St Rose E; Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA.
  • Orevillo C; Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA.
  • Strom S; Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor, Morristown, NJ, 07960, USA.
  • Fischer T; Pearl Therapeutics Inc., Durham, NC, USA.
  • Golden M; Pearl Therapeutics Inc., Durham, NC, USA.
  • Dwivedi S; Pearl Therapeutics Inc., Durham, NC, USA.
Respir Res ; 18(1): 158, 2017 08 21.
Article em En | MEDLINE | ID: mdl-28826397
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2017 Tipo de documento: Article